REPRIEVE


Study Description: This study will use pitavastatin to try to decrease the risk of major heart-related events, such as heart attacks and strokes, in HIV-positive adults age 40-75 years who are taking HIV medications. Pitavastatin and other statins are approved to lower blood cholesterol, but have also been found to lower inflammation chemicals in the blood that are known to contribute to heart disease. HIV-infected adults have higher levels of inflammation chemicals, and are at higher risk for heart disease and heart-related events than those without HIV disease.

Contact for Enrollment

    
     (706) 721-1249
    vowhite@augusta.edu

    Submit Information Online

Principal Investigator: Rodger MacArthur

Eligibility Criteria: Inclusion: HIV-positive adults age 40-75 years on HIV medications for at least 6 months not currently on any cholesterol-lowering medication nor a clinical need to begin any. Exclusion: No current or past history of heart disease other than high blood pressure no current or past health conditions that the study does not allow no pregnant or breastfeeding women.

Compensation: Yes, subjects will be compensated.

Compensation Explanation: Subjects will be paid $25.00 for each required study visit that they complete, beginning with the Entry Visit. They will be paid at the time of their study visits. Because there is the likelihood of total compensation being more than $100 in nearly every patient, they will complete a W-9 form at the Entry visit. Stipends will be paid using the ClinCard system.

 

Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.